Arctic Bioscience - Board/Management Information 2022

Arctic Bioscience - CFO change

Arctic Bioscience, a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on the unique properties of

bioactive marine compounds, announces that CFO Danielle Glenn has terminated her

consulting agreement and accepted a position with another company. Glenn has

been with the company since September 2020. The search for a new permanent CFO

has been initiated.

"Arctic Bioscience has taken major steps over the past years, with several

initiatives in both pharma and nutraceuticals and the development of a new

production facility at the North- West coast of Norway. In addition, the company

has listed on the Euronext Growth platform, supporting the company's growth

strategy. I would like to thank Danielle for her contributions to this

development", says Harald Nordal, Chairman of the Board in Arctic Bioscience.

"Arctic Bioscience will continue to capture its commercial and strategic

opportunities, develop new alliances and execute on the upcoming phase II study

for our psoriasis drug candidate. Our incoming CEO Christer Valderhaug will

align his management team, including the new CFO with this exciting growth

strategy ", says Nordal

Danielle Glenn will continue as CFO through April 2022.

For more information, please contact

Harald Nordal, COB Arctic Bioscience

Phone: +47 908 59 397

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical products based on herring roe oil. Herring roe oil contains lipids

that are essential to maintain cell membranes, contributing to normal

functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience

are sold globally as bulk ingredients to other companies making dietary

supplements, and as finished goods under the Romega brand. The strategy is to

switch sales from bulk to finished goods and focus markets are USA and China.

The company is developing HRO350 - a novel investigational drug candidate with

herring roe as raw material. HRO350 is being developed for treatment of mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines. Arctic Bioscience is led by a team of highly competent people with

experience in developing marine oils and experience from global pharmaceutical

companies.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI assistant